Interestingly, CCI-779 (also called temsirolimus), a derivative of rapamycin, is also an mTOR inhibitor and has been studied combined with bortezomib in relapsed or relapsed refractory multiple myeloma (NCT00483262). This evidence concerns the gene MTOR and plasma cell myeloma.